Jeffrey Dunn, PharmD, MBA

The key opinion leader discusses how criteria for assisted reproductive technology (ART) coverage are established, including stepwise approaches and considerations for mixed protocols, while emphasizing the importance of collaboration between providers and payers to ensure patient access to various ARTs.

Jeffrey Dunn, Pharm.D., MBA, discusses how comparison trials for different assisted reproductive technologies (ARTs) are necessary to evaluate their relative efficacy, safety and cost-effectiveness, with specific focus on a trial comparing highly purified human menotropin (HP-hMG) and recombinant follicle-stimulating hormone (FSH), as well as a study examining the impact of health benefit design for ART on pregnancy outcomes.